With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. | Despite the largely stagnant performance ...
Zacks Investment Research on MSN
Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains
Bayer AG BAYRY reported third-quarter 2025 core earnings of 17 cents per American Depositary Receipt (ADR), which comfortably ...
Investing.com -- Bayer AG (ETR:BAYGN) on Wednesday reported a 138% jump in quarterly earnings, lifted by higher margins in ...
Bayer AG won support from US regulators for a menopause drug that’s expected to hit the market in November under the name of Lynkuet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback